Tumor Virus Infections: Clinical Trials

2,052 trials for Tumor Virus Infections, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

1040 completed, 265 recruiting, 226 unknown, 196 terminated. 698 Phase 2, 622 Phase 1, 296 Not applicable, 242 Phase 3, 56 Phase 4.

By phase and status

PhaseTrialsStatus
Phase 2698Completed 332, Recruiting 94, Terminated 91, Unknown 57, Active not recruiting 50, Withdrawn 42, Not yet recruiting 27, Suspended 3, Enrolling by invitation 2
Phase 1622Completed 296, Terminated 94, Recruiting 87, Unknown 50, Active not recruiting 41, Withdrawn 27, Not yet recruiting 22, Suspended 3, Enrolling by invitation 2
Not applicable296Completed 150, Recruiting 47, Unknown 40, Terminated 18, Active not recruiting 17, Not yet recruiting 16, Withdrawn 6, Enrolling by invitation 2
Phase 3242Completed 144, Unknown 31, Active not recruiting 26, Recruiting 21, Terminated 11, Not yet recruiting 5, Withdrawn 4
Phase 456Completed 23, Recruiting 11, Unknown 11, Active not recruiting 6, Terminated 3, Enrolling by invitation 1, Withdrawn 1
Early Phase 139Unknown 13, Not yet recruiting 7, Completed 6, Recruiting 6, Terminated 3, Active not recruiting 2, Withdrawn 2

Follow Tumor Virus Infections: new trials by email Literature Review of Tumor Virus Infections trials Research Report on Tumor Virus Infections

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Efficacy and Safety of SR-T100 Gel in Common Warts (CW) Patients
Vehicle gel, SR-T100 gel with 1.0% of SM, SR-T100 gel with 2.3% of SM - Common Wart
Phase 2SuspendedG&E Herbal Biotechnology Co., LTD1022030-09-012023-09-14
Maximizing HPV Vaccination: Real-time Reminders, Guidance, and Recommendations - Part 4: Feasibility Trial
Protect Me 4 Application + External Quality Improvement Support, Protect Me 4 Application Alone - Human Papillomavirus (HPV) Vaccines
Not applicableNot yet recruitingUniversity of Florida12962027-09-152026-09-14
Testing the Addition of a New Anti-Cancer Drug, Glofitamab to Usual Chemotherapy for Burkitt and Double Hit Lymphoma
Biospecimen Collection, Bone Marrow Biopsy, Carboplatin - Recurrent Burkitt Lymphoma, Recurrent High Grade B-Cell Lymphoma With MYC and BCL2 Rearrangements
Phase 2 / Phase 3RecruitingNational Cancer Institute (NCI)2712027-07-272026-11-17
Papilozumib Vaginal Gel for Exocervical Mucosal Restoration in Women With Human Papillomavirus (HPV)
Papilozumib vaginal gel, Papilozumib oral supplement - Human Papillomavirus Infection, Human Papillomavirus Infections
Not applicableNot yet recruitingHifas da Terra S.L.812027-07-012026-10-05
Incidence of HPV Infection and HPV-Associated Disease in Screening Indian Men Who Have Sex With HIV-Positive Men
Cytology Specimen Collection Procedure, High Resolution Anoscopy with Biopsy, Laboratory Biomarker Analysis - HIV Infection, Human Papillomavirus Infection
WithdrawnAIDS Malignancy Consortium2027-04-302025-06-06
Genetically Engineered Cells (BAFFR-CAR T Cells) for the Treatment of Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia and B-cell Lymphoblastic Lymphoma
Autologous BAFFR-targeting CAR T Cells, Biospecimen Collection, Bone Marrow Aspiration - Recurrent B Acute Lymphoblastic Leukemia, Recurrent B Lymphoblastic Lymphoma
Phase 1RecruitingCity of Hope Medical Center162027-04-172026-11-13
Phase I Safety Clinical Trial of Anti-CD19 CAR-T Therapy COL01 for the Treatment of Adults With Relapsed or Refractory B-cell Lymphoid Neoplasms: First-in-human Administration, COLIBRI.
CAR-T anti-CD19 COL01 - Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia, Lymphoid Malignancies
Phase 1Not yet recruitingGUSTAVO SALGUERO122027-04-012026-10-20
Asciminib and Inotuzumab Ozogamicin for Relapsed or Refractory Philadelphia Chromosome-positive B-cell Acute Lymphoblastic Leukemia (R/R Ph+ B-ALL)
Asciminib, Inotuzumab ozogamicin - B-cell Acute Lymphoblastic Leukemia (B-ALL)
Phase 1RecruitingSunil G. Iyer452027-03-312026-11-13
PROTECT-HER KIT to Improve HPV Self-Sampling Uptake Among Women in Selangor
PROTECT-HER KIT (Protection Motivation Theory-Based HPV Screening Education Kit), Standard Ministry of Health (MOH) Educational Materials - Cervical Cancer Screening, Human Papillomavirus Infection
Not applicableNot yet recruitingUniversiti Teknologi Mara1062027-03-012026-11-17
Efficacy and Safety of Oral Ivermectin for Genital Warts
Ivermectin - Genital Warts
Not applicableNot yet recruitingUniversity of Health Sciences Lahore902027-02-202026-11-03
Metabolically Fit CD19 CAR T Cells With CD34 Selection Markers in Adults With CD19-Positive B-Cell Acute Lymphocytic Leukemia
Fludarabine, Cyclophosphamide, Levetiracetam - CD19 Positive, B-ALL
Phase 1Not yet recruitingMedical University of South Carolina182027-02-012026-11-13
Combining Neo-adjuvant ATR-inhibition With Nodal SBRT for Early-stage Resectable HPV+ OPSCCs
ATRN-119, Stereotactic Body Radiation Therapy (SBRT) - HPV Positive Oropharyngeal Squamous Cell Carcinoma, Squamous Cell Carcinoma
Phase 1 / Phase 2Not yet recruitingAbramson Cancer Center at Penn Medicine352027-01-312026-10-27
Testing the Safety of Anti-Cancer Drug, CX-5461 (Pidnarulex), in Treating Lymphoma With Specific Changes in the MYC Gene
Biopsy Procedure, Biospecimen Collection, Computed Tomography - Burkitt Lymphoma, Double-Expressor Lymphoma
Phase 1 / Phase 2RecruitingNational Cancer Institute (NCI)502027-01-112026-10-14
Depletion of CD45RA Positive Naive T Cells for the Prevention of Graft Versus Host Disease in Older Patients Undergoing Allogeneic Hematopoietic Cell Transplantation for Acute Leukemia or Myelodysplastic Syndrome
Allogeneic CD34+-enriched and CD45RA-depleted PBSCs, Biospecimen Collection, Bone Marrow Aspiration - Acute Biphenotypic Leukemia, Acute Leukemia
Phase 2Not yet recruitingFred Hutchinson Cancer Center522027-01-012026-09-14
Study Of KITE-753 in R/R B-Cell ALL
KITE-753 - B-cell Acute Lymphoblastic Leukemia
Phase 1Not yet recruitingM.D. Anderson Cancer Center182026-12-312026-09-11
Zopapogene Imadenovec for the Treatment of Recurrent Respiratory Papillomatosis in Children
Zopapogene imadenovec-drba - Recurrent Respiratory Papillomatosis (RRP), Juvenile-onset Recurrent Respiratory Papillomatosis
Phase 3Not yet recruitingPrecigen, Inc152026-12-312026-10-28
Five-Year Multicenter Cohort Study of Vaginal Microbiome and STIs Progression
STIs
Not yet recruitingShenzhen Maternity & Child Healthcare Hospital75742026-12-202026-11-17
Phase 1 Trial to Evaluate Safety and Immunogenicity of MVA-BN-EBV in Healthy Young Adults
MVA-BN-EBV, Placebo - Epstein Barr Virus (EBV) Infection
Phase 1Not yet recruitingBavarian Nordic152026-12-152026-10-22
A Study of Sonrotoclax (BGB-11417) in Children With Relapsed or Refractory Acute Myeloid Leukemia and B-cell Acute Lymphoblastic Leukemia
sonrotoclax, Azacitidine, Inotuzumab ozogamicin - Relapsed Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia
Phase 1 / Phase 2Not yet recruitingBeOne Medicines302026-12-012026-10-26
Rituximab for PTLD Prevention in Solid Organ Transplant Recipients With EBV DNAemia
Rituximab - PTLD, Epstein Barr Virus (EBV) Infection
Phase 1Not yet recruitingJennifer Amengual282026-12-012026-09-17

Showing 20 of 2052. Sign in to see all of them.

Narrower conditions

Burkitt Lymphoma (978)  ·  Precursor Cell Lymphoblastic Leukemia-Lymphoma (585)  ·  Lymphoma, Large B-Cell, Diffuse (576)  ·  Papillomavirus Infections (573)  ·  Lymphoma, Follicular (522)  ·  Lymphoma, Mantle-Cell (509)  ·  Lymphoma, Non-Hodgkin (503)  ·  Leukemia, Lymphocytic, Chronic, B-Cell (464)  ·  Lymphoma, B-Cell, Marginal Zone (458)  ·  Lymphoma (453)  ·  Lymphoma, Large-Cell, Immunoblastic (445)  ·  Hodgkin Disease (354)  ·  Leukemia (267)  ·  Lymphoma, T-Cell, Cutaneous (255)  ·  Leukemia, Myeloid, Acute (253)

Broader conditions

DNA Virus Infections (2043)  ·  Virus Diseases (2027)  ·  Infections (1994)  ·  Neoplasms (1387)  ·  Pathological Conditions, Signs and Symptoms (1295)  ·  Pathologic Processes (1288)  ·  Disease Attributes (1243)  ·  Neoplasms by Histologic Type (1206)  ·  Herpesviridae Infections (1150)  ·  Immune System Diseases (1112)  ·  Hemic and Lymphatic Diseases (1044)  ·  Lymphatic Diseases (1040)  ·  Immunoproliferative Disorders (1031)  ·  Lymphoproliferative Disorders (990)

Interventions

Cyclophosphamide (239)  ·  Rituximab (120)  ·  Etoposide (107)  ·  Methotrexate (96)  ·  Vincristine (95)  ·  Filgrastim (94)  ·  Peripheral Blood Stem Cell Transplantation (94)  ·  Cytarabine (93)  ·  fludarabine phosphate (89)  ·  Radiotherapy (78)  ·  Doxorubicin (73)  ·  Prednisone (71)  ·  Dexamethasone (62)  ·  fludarabine (55)  ·  Cyclosporine (53)

Sponsors

National Cancer Institute (NCI) (148)  ·  GlaxoSmithKline (72)  ·  Fred Hutchinson Cancer Center (64)  ·  Merck Sharp & Dohme LLC (54)  ·  M.D. Anderson Cancer Center (40)  ·  Memorial Sloan Kettering Cancer Center (32)  ·  City of Hope Medical Center (28)  ·  Children's Oncology Group (25)  ·  Masonic Cancer Center, University of Minnesota (25)  ·  Case Comprehensive Cancer Center (23)  ·  Mayo Clinic (21)  ·  National Institute of Allergy and Infectious Diseases (NIAID) (19)  ·  University of Washington (19)  ·  Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins (18)  ·  Baylor College of Medicine (17)

Countries

United States (1131)  ·  China (223)  ·  Canada (110)  ·  France (106)  ·  Italy (83)  ·  Germany (74)  ·  Australia (73)  ·  Spain (67)  ·  United Kingdom (67)  ·  Belgium (51)  ·  Netherlands (36)  ·  Puerto Rico (36)  ·  Taiwan (35)  ·  South Korea (34)  ·  Switzerland (34)

Top investigators

Ajay Gopal (9)  ·  Elias Jabbour (7)  ·  Helen E Heslop, MD (6)  ·  Philip L. McCarthy, MD (6)  ·  Christos E. Emmanouilides, MD (5)  ·  David Maloney (5)  ·  Elias Jabbour, MD (5)  ·  Ibrahim Aldoss (5)  ·  Joel Palefsky, MD (5)  ·  Jun Zhang, Master (5)  ·  Roger Strair, MD, PhD (5)

Results publications

PMID 41276263, PMID 41671463, PMID 35622074, PMID 34515338, PMID 27422279, PMID 32499241, PMID 19935017, PMID 32184277, PMID 31824976, PMID 19236277, PMID 19236279, PMID 24731816, PMID 25424785, PMID 25424918, PMID 29074187, PMID 29211620, PMID 30982556, PMID 32589970, PMID 33857679, PMID 35149535, PMID 38551807, PMID 41166720, PMID 15897380, PMID 17242396, PMID 17628649, PMID 18515521, PMID 19586656, PMID 19949018, PMID 20028764, PMID 20949623, PMID 21471141, PMID 21527516, PMID 22002018, PMID 22265115, PMID 22337718, PMID 22454089, PMID 23066159, PMID 23299013, PMID 23336207, PMID 23632723, PMID 24862638, PMID 25057165, PMID 25273231, PMID 25424783, PMID 27566633, PMID 29214505, PMID 29269325, PMID 29767739, PMID 29995724, PMID 31464859

NIH funding

P30CA015704 (25), P30CA033572 (24), P30CA043703 (18), U10CA032102 (17), P30CA006973 (14), P30CA015083 (12), U01CA121947 (12), U10CA180886 (12), 2023 (11), P30CA022453 (11), 2018 (10), 2016 (9), P30CA016672 (9), P30CA072720 (9), U01CA097452 (9)